• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form F-3/A filed by SciSparc Ltd.

    6/10/25 5:30:47 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRC alert in real time by email
    F-3/A 1 ea0245232-f3a1_scisparc.htm AMENDMENT NO. 1 TO FORM F-3

    As filed with the Securities and Exchange Commission on June 10, 2025

    Registration No. 333-286099

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    AMENDMENT NO. 1 TO

    FORM F-3

     

    REGISTRATION STATEMENT
    UNDER THE SECURITIES ACT OF 1933

     

    SCISPARC LTD.

    (Exact name of registrant as specified in its charter)

     

    Not Applicable

    (Translation of Registrant’s Name into English)

     

    State of Israel   Not Applicable
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

      

    20 Raul Wallenberg Street, Tower A,

    Tel Aviv 6971916 Israel

    Tel: (+972) (3) 717-5777

    (Address and telephone number of registrant’s principal executive offices)

     

    Puglisi & Associates

    850 Library Ave., Suite 204

    Newark, DE 19711

    Tel: (302) 738-6680

    (Name, address, and telephone number of agent for service)

     

    Copies to:

     

    Dr. Shachar Hadar, Adv.

    Meitar | Law Offices

    16 Abba Hillel Silver Rd.

    Ramat Gan 52506, Israel

    Tel: (+972) (3) 610-3100

      Oded Har-Even, Esq.
    Howard Berkenblit, Esq.
    Sullivan & Worcester LLP
    1251 Avenue of the Americas
    New York, NY 10020
    Tel: (212) 660-3000

     

    Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.

     

    If only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐ 

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒ 

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ 

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ 

     

    If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.  

     

    Emerging growth company ☐

     

    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐  

     

    †The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

     

    The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    SciSparc Ltd. (the “Company”) is filing this Amendment No. 1 (this “Amendment No. 1”) to the Registration Statement on Form F-3 (File No. 333-286099) originally filed on March 25, 2025 (the “Registration Statement”) solely for the purpose of updating the consent of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, independent registered public accounting firm for the Company, filed as Exhibit 23.1 to the Registration Statement.

     

    Other than expressly set forth herein, this Amendment No. 1 does not, and does not purport to, amend or restate any other information contained in the Registration Statement nor does this Amendment No. 1 reflect any events that have occurred after the Registration Statement was filed.

     

    1

     

     

    Item 9. Exhibits.

     

    Exhibit No.   Exhibit Description   Form     File No.     Exhibit No.   Filing Date
    3.1   Amended and Restated Articles of Association of SciSparc Ltd.   F-3   333-269839   3.1   February 16, 2023
    4.1   Form of Convertible Debenture   6-K   001-38041   4.1   February 27, 2025
    4.2   Form of Warrant to purchase Ordinary Shares     6-K   001-38041   4.2   February 27, 2025
    5.1**   Opinion of Meitar Law Offices.                
    10.1   Securities Purchase Agreement, dated February 24, 2025 by and between SciSparc Ltd. and each of the investors on the Schedule of Buyers as Schedule 1 thereto.   6-K   001-38041   10.1   February 27, 2025
    10.2   Securities Purchase Agreement, dated February 25, 2025, between SciSparc Ltd. and the investor on the Schedule of Buyers as Schedule 1 thereto.     6-K   001-38041   10.2   February 27, 2025
    10.3   Global Guaranty Agreement, dated February 25, 2025, by Brain Bright Ltd. and Evero Health Ltd. in favor of the Investor.   6-K   001-38041   10.3   February 27, 2025
    10.4   Registration Rights Agreement, dated February 25, 2025, by and between the Investor and SciSparc Ltd.   6-K   001-38041   10.4   February 27, 2025
    23.1*   Consent of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, independent registered accounting firm for the Registrant.                
    23.2   Consent of Ben David Shalvi Kop & Co, independent registered accounting firm for AutoMax Motors Ltd.   6-K   001-38041   99.3  

    June 9, 2025 

    23.3**   Consent of Meitar (included in Exhibit 5.1)                
    24.1**   Power of Attorney (included in the signature page of this registration statement).                
    107**   Calculation of Registration Fee Table                

     

    * Filed herewith
    ** Previously Filed

     

    Item 10. Undertakings

     

    (a)The undersigned Registrant hereby undertakes:

     

    1.To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i)To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

     

      (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

     

      (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    II-1

     

     

    provided, however, that paragraphs (a)(1)(i), (a)(1)(ii) and a(l)(iii) do not apply if the registration statement is on Form S-3 or Form F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

     

    (2)That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (4)To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Act need not be furnished, provided, that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Act or Rule 3-19 of this chapter if such financial statements and information are contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Form F-3.

     

    (5)That, for the purpose of determining liability under the Securities Act to any purchaser:

     

      (i) If the Registrant is relying on Rule 430B:

     

      A. Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

     

      B. Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

     

    II-2

     

     

      (ii) If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

     

    (6)That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

     

      (i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

     

      (ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

     

      (iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

     

      (iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

     

    (b)Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933, as amended, and will be governed by the final adjudication of such issue.

     

    II-3

     

      

    SIGNATURES

     

    Pursuant to the requirement of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, the City of Tel Aviv, State of Israel on June 10, 2025.

     

    SCISPARC LTD.
         
    By: /s/ Oz Adler  
      Oz Adler  
      Chief Executive Officer  

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by each of the following persons in the capacities and on the dates indicated:

     

    Signature   Title   Date
             
    /s/ Oz Adler   Chief Executive Officer and Chief Financial Officer   June 10, 2025
    Oz Adler   (Principal Executive Officer and Principal Accounting Officer)    
             
    *   Chairman of the Board of Directors   June 10, 2025
    Amitay Weiss        
             
    *   President and Director   June 10, 2025
    Itschak Shrem        
             
    *   Director   June 10, 2025
    Amnon Ben Shay        
             
    *   Director   June 10, 2025
    Alon Dayan        
             
    *   Director   June 10, 2025
    Moshe Revach        
             
    *   Director   June 10, 2025
    Liat Sidi        
             
    *   Director   June 10, 2025
    Lior Vider        

     

    *By:/s/ Oz Adler  
    Name: Oz Adler  
    Title:Attorney-in-Fact  

     

    II-4

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the Securities Act of 1933, as amended, the undersigned, Puglisi & Associates duly authorized representative in the United States of SciSparc Ltd., has signed this registration statement on June 10, 2025.

     

    Puglisi & Associates  
       
    /s/ Donald J. Puglisi  

    Donald J. Puglisi

    Managing Director

     

     

     

    II-5

     

    Get the next $SPRC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SPRC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SciSparc Announces Publication of Japanese Patent Application

      TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the publication of a Japanese divisional patent. The patent application introduces a novel pharmaceutical combination of paracetamol and palmitoylethanolamide (PEA) that may enhance pain relief and fever relief with lower doses and fewer side effects compared to paracetamol monotherapy, with potential for safer and more effective treatment for millions worldwide. "This patent represents a significant innovation

      5/27/25 7:32:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

      Patent publication in Europe strengthens Clearmind's global IP position and advances strategic focus on addiction treatment Vancouver, Canada, May 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today the official publication of a European patent application by the European Patent Office (EPO). This patent, numbered EP 4531826, covers Clearmind's proprietary psychedelic-based combination therapy, which includes MEAI (5-methoxy-2-aminoindane) and certain N-Acyl

      5/12/25 7:32:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

      TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind") has led to the publication of a European patent application by the European Patent Office. The patent application relates to a combination treatment using Clearmind's 5-methoxy-2-aminoindane ("MEAI") and SciSparc's Palmitoylethanolamide for the treatment of cocaine addiction. The patent is based on preclinical trial results led by Pro

      5/12/25 7:32:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    Financials

    Live finance-specific insights

    See more
    • SciSparc Adopts Limited Duration Shareholder Rights Plan

      TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its Board of Directors (the "Board") has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately. "Today we announced exciting positive results from our weight loss and metabolic disorder program with our proprietary psychedelic-based treatment," said Oz Adler, SciSparc's Chief Executive Officer. "Unfortunately, SciSparc, like many other clinical-stag

      11/28/23 8:55:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel

      SciSparc seeks to scale up revenues and will consider transferring its pharmaceutical activities to a separate legal entity and exploring the possibility of dividend distribution TEL AVIV, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the signing of a non-binding letter of intent to merge with a leading vehicle importer company in Israel (the "Target Company"). This merger (the "Merger) is expected to be consummated by means of a reverse triangular merger, pursua

      11/22/23 7:42:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

      Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announces today that its previously announced reverse share split of its issued and outstanding ordinary shares, no par value at a ratio of 1-for-26, is expected to be implemented after market close today. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at

      9/27/23 7:58:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    SEC Filings

    See more
    • Amendment: SEC Form F-3/A filed by SciSparc Ltd.

      F-3/A - SciSparc Ltd. (0001611746) (Filer)

      6/10/25 5:30:47 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by SciSparc Ltd.

      6-K - SciSparc Ltd. (0001611746) (Filer)

      6/9/25 4:00:32 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form F-4/A filed by SciSparc Ltd.

      F-4/A - SciSparc Ltd. (0001611746) (Filer)

      5/27/25 4:02:31 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SPRC
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form SC 13G filed by SciSparc Ltd.

      SC 13G - SciSparc Ltd. (0001611746) (Subject)

      3/6/24 5:02:18 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by SciSparc Ltd.

      SC 13G - SciSparc Ltd. (0001611746) (Filed by)

      12/13/22 6:22:30 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by SciSparc Ltd. (Amendment)

      SC 13G/A - SciSparc Ltd. (0001611746) (Subject)

      5/9/22 4:08:30 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

      As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of its restructuring plans to unlock value for shareholders, it has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities. Mr. Baranes is a business strategy expert with a

      5/30/23 8:40:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

      JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the appointment of Prof. Ciro Leonardo Pierri as special advisor for MitoCareX Bio Ltd. ("MitoCareX Bio"), SciSparc's recently established joint venture ("JV") for the discovery and development of potential drugs for cancers, infectious diseases and other life-threatening conditions. Prof. Pierri is a biochemist and serves as an associate professor at the U

      6/15/22 8:30:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

      Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroed

      3/30/22 8:30:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care